A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue
| Autor: | H. F. Hope-Stone, C. G. Fowler, B. S. Mantell, Maurice L. Slevin, C. J. Gallagher, D. H. Oram, R. T. D. Oliver, P. R. Blake |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
endocrine system medicine.medical_specialty medicine.medical_treatment Urology Adenocarcinoma Endometrium Gonadotropin-Releasing Hormone Subcutaneous injection medicine Humans Outpatient clinic Adverse effect Aged Aged 80 and over Gynecology Chemotherapy business.industry Endometrial cancer Obstetrics and Gynecology Middle Aged Prognosis medicine.disease Endometrial Neoplasms Radiation therapy medicine.anatomical_structure Drug Evaluation Female business hormones hormone substitutes and hormone antagonists Hormone |
| Zdroj: | BJOG: An International Journal of Obstetrics and Gynaecology. 98:1037-1041 |
| ISSN: | 1471-0528 1470-0328 |
| DOI: | 10.1111/j.1471-0528.1991.tb15343.x |
| Popis: | Objective— To test the antitumour effect of gonadotrophin releasing-hormone (GnRH) analogues in women with recurrent endometrial cancer. Design— An open phase II observational trial of GnRH analogues. Serial measurements of gonadotrophins, sex hormones and tumour dimensions were made together with repeat biopsy when possible to assess the response to treatment. Setting— The outpatient clinics of the Department of Medical Oncology at The Royal London, Royal Marsden and St Bartholomew's hospitals. Subjects— 17 patients with endometrial cancer which had recurred after surgery, radiotherapy and progesterone treatment and was symptomatic, progressive and assessable for response. Intervention— Monthly subcutaneous injection of GnRH analogue. Main outcome measures— Reduction in serum gonadotrophins and reduction in tumour dimensions. Results— Six out of 17 patients (35%, 95% CI 12.6–58%) achieved a complete or partial remission which continues for a median of 20 months with no adverse effects. Conclusion— GnRH analogues have a significant antitumour effect in recurrent endometrial cancer which warrants further examination in comparison with progestogens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text